US20190060482A1 - Cationic lipid compositions for tissue-specific delivery - Google Patents

Cationic lipid compositions for tissue-specific delivery Download PDF

Info

Publication number
US20190060482A1
US20190060482A1 US16/038,107 US201816038107A US2019060482A1 US 20190060482 A1 US20190060482 A1 US 20190060482A1 US 201816038107 A US201816038107 A US 201816038107A US 2019060482 A1 US2019060482 A1 US 2019060482A1
Authority
US
United States
Prior art keywords
substituted
molar ratio
lipid
unsubstituted
compositional molar
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US16/038,107
Other languages
English (en)
Inventor
Shikha MISHRA
Xavier de Mollerat du Jeu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Life Technologies Corp
Original Assignee
Life Technologies Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Life Technologies Corp filed Critical Life Technologies Corp
Priority to US16/038,107 priority Critical patent/US20190060482A1/en
Assigned to Life Technologies Corporation reassignment Life Technologies Corporation ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: DE MOLLERAT DU JEU, XAVIER, MISHRA, SHIKHA
Publication of US20190060482A1 publication Critical patent/US20190060482A1/en
Priority to US17/378,466 priority patent/US20220001023A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6917—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a lipoprotein vesicle, e.g. HDL or LDL proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/541—Organic ions forming an ion pair complex with the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases RNAses, DNAses
US16/038,107 2017-08-31 2018-07-17 Cationic lipid compositions for tissue-specific delivery Abandoned US20190060482A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US16/038,107 US20190060482A1 (en) 2017-08-31 2018-07-17 Cationic lipid compositions for tissue-specific delivery
US17/378,466 US20220001023A1 (en) 2017-08-31 2021-07-16 Cationic lipid compositions for tissue-specific delivery

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762552783P 2017-08-31 2017-08-31
US16/038,107 US20190060482A1 (en) 2017-08-31 2018-07-17 Cationic lipid compositions for tissue-specific delivery

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US17/378,466 Continuation US20220001023A1 (en) 2017-08-31 2021-07-16 Cationic lipid compositions for tissue-specific delivery

Publications (1)

Publication Number Publication Date
US20190060482A1 true US20190060482A1 (en) 2019-02-28

Family

ID=63104088

Family Applications (2)

Application Number Title Priority Date Filing Date
US16/038,107 Abandoned US20190060482A1 (en) 2017-08-31 2018-07-17 Cationic lipid compositions for tissue-specific delivery
US17/378,466 Pending US20220001023A1 (en) 2017-08-31 2021-07-16 Cationic lipid compositions for tissue-specific delivery

Family Applications After (1)

Application Number Title Priority Date Filing Date
US17/378,466 Pending US20220001023A1 (en) 2017-08-31 2021-07-16 Cationic lipid compositions for tissue-specific delivery

Country Status (8)

Country Link
US (2) US20190060482A1 (lt)
EP (1) EP3675826B1 (lt)
JP (2) JP7379325B2 (lt)
CN (1) CN111065377A (lt)
AU (1) AU2018324345A1 (lt)
CA (1) CA3073851A1 (lt)
LT (1) LT3675826T (lt)
WO (1) WO2019045897A1 (lt)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020212522A1 (en) 2019-04-16 2020-10-22 Genfit Compositions and methods for the stabilization of micro-rna
WO2021003462A1 (en) * 2019-07-03 2021-01-07 Factor Bioscience Inc. Cationic lipids and uses thereof
EP3865122A1 (en) * 2020-02-11 2021-08-18 Pantherna Therapeutics GmbH Lipid composition and use thereof for delivery of a therapeutically active agent to endothelium
US11242311B2 (en) 2019-07-30 2022-02-08 Factor Bioscience Inc. Cationic lipids and transfection methods
US11690921B2 (en) * 2018-05-18 2023-07-04 Sangamo Therapeutics, Inc. Delivery of target specific nucleases
WO2024006937A1 (en) 2022-06-30 2024-01-04 Life Technologies Corporation Lipid compositions for in vivo delivery

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US5235033A (en) 1985-03-15 1993-08-10 Anti-Gene Development Group Alpha-morpholino ribonucleoside derivatives and polymers thereof
PT1129064E (pt) * 1998-11-12 2008-01-31 Invitrogen Corp Reagentes de transfecção
US20110200582A1 (en) * 2009-12-23 2011-08-18 Novartis Ag Lipids, lipid compositions, and methods of using them
DK2640700T3 (en) * 2010-11-15 2019-01-14 Life Technologies Corp AMINOUS TRANSFECTION REAGENTS AND METHODS FOR PREPARING USE THEREOF
CN106572974B (zh) * 2014-07-15 2021-04-23 生命技术公司 用于将分子有效递送到细胞的具有脂质聚集体的组合物和方法
JP6715325B2 (ja) * 2015-06-26 2020-07-01 スーチョウ リボ ライフ サイエンス カンパニー、リミテッドＳｕｚｈｏｕ Ｒｉｂｏ Ｌｉｆｅ Ｓｃｉｅｎｃｅ Ｃｏ．， Ｌｔｄ． ｓｉＲＮＡ、ｓｉＲＮＡを含む医薬組成物及び結合体、並びにそれらの応用

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11690921B2 (en) * 2018-05-18 2023-07-04 Sangamo Therapeutics, Inc. Delivery of target specific nucleases
WO2020212522A1 (en) 2019-04-16 2020-10-22 Genfit Compositions and methods for the stabilization of micro-rna
EP4223886A2 (en) 2019-04-16 2023-08-09 Genfit Compositions and methods for the stabilization of micro-rna
WO2021003462A1 (en) * 2019-07-03 2021-01-07 Factor Bioscience Inc. Cationic lipids and uses thereof
CN114450265A (zh) * 2019-07-03 2022-05-06 菲克特生物科学股份有限公司 阳离子脂质及其用途
EP3997059A4 (en) * 2019-07-03 2023-12-13 Factor Bioscience Inc. CATIONIC LIPIDS AND THEIR USES
US11242311B2 (en) 2019-07-30 2022-02-08 Factor Bioscience Inc. Cationic lipids and transfection methods
US11814333B2 (en) 2019-07-30 2023-11-14 Factor Bioscience Inc. Cationic lipids and transfection methods
EP3865122A1 (en) * 2020-02-11 2021-08-18 Pantherna Therapeutics GmbH Lipid composition and use thereof for delivery of a therapeutically active agent to endothelium
CN115087437A (zh) * 2020-02-11 2022-09-20 潘泽尔纳疗法有限公司 脂质组合物及其用于将治疗活性剂递送至内皮的用途
WO2024006937A1 (en) 2022-06-30 2024-01-04 Life Technologies Corporation Lipid compositions for in vivo delivery

Also Published As

Publication number Publication date
JP2020532546A (ja) 2020-11-12
EP3675826B1 (en) 2023-05-31
EP3675826A1 (en) 2020-07-08
LT3675826T (lt) 2023-09-11
WO2019045897A1 (en) 2019-03-07
JP7379325B2 (ja) 2023-11-14
CN111065377A (zh) 2020-04-24
US20220001023A1 (en) 2022-01-06
CA3073851A1 (en) 2019-03-07
AU2018324345A1 (en) 2020-03-05
JP2023138526A (ja) 2023-10-02

Similar Documents

Publication Publication Date Title
US20220001023A1 (en) Cationic lipid compositions for tissue-specific delivery
Kulkarni et al. Lipid nanoparticles enabling gene therapies: from concepts to clinical utility
Hou et al. Lipid nanoparticles for mRNA delivery
CN103906527B (zh) Mrna递送的脂质纳米颗粒组合物和方法
EP3628335B1 (en) Lipidic nanoparticles for mrna delivery in the lungs
Templeton Cationic liposomes as in vivo delivery vehicles
JP2022518504A (ja) 閉端ｄｎａ（ｃｅｄｎａ）ならびに遺伝子療法または核酸療法に関連する免疫応答を低減させる方法における使用
US20220047723A1 (en) OPTIMIZED mRNA ENCODING CAS9 FOR USE IN LNPs
WO2021231827A2 (en) Sirna sequences targeting coronavirus-2
Nsairat et al. Recent advances in using liposomes for delivery of nucleic acid-based therapeutics
KR20230138496A (ko) 핵산 전달에 적합한 지질
US20230263819A1 (en) Lipid Composition and Use Thereof for Delivery of a Therapeutically Active Agent to Endothelium
PT103865A (pt) Nano-transportadores de base lipídica para entrega direccionada de vectores virais e processo para a sua produção
WO2014030601A1 (ja) アニオン性を有する新規ナノバブルポリ－リポ・プレックスの製造方法
KR20220117133A (ko) 양이온성 분자 수송체 및 SARS-CoV-2 mRNA의 이온 복합체를 포함하는 코로나바이러스감염증-19 예방 백신 조성물
Templeton et al. Optimization of non-viral gene therapeutics using bilamellar invaginated vesicles
Lu et al. Enhancement of p53 gene transfer efficiency in hepatic tumor mediated by transferrin receptor through trans-arterial delivery
Smyth Templeton Myths concerning the use of cationic liposomes in vivo
Templeton Liposomal Nonviral Delivery Vehicles
KR20240006456A (ko) 핵산 전달을 위한 국소 전달용 양이온성 콜레스테롤사용 지질나노입자
Chen Lipid nanoparticles for delivery of nucleic acid therapeutics
KR20130049668A (ko) 저밀도 지단백질 유사 양이온성 나노입자로 된 혈액 뇌 장벽（ｂｂｂ） 수송 벡터
CN117897143A (zh) Apoe和apob修饰的脂质纳米颗粒组合物及其用途
NZ618275B2 (en) Lipid nanoparticle compositions and methods for mrna delivery

Legal Events

Date Code Title Description
AS Assignment

Owner name: LIFE TECHNOLOGIES CORPORATION, CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:MISHRA, SHIKHA;DE MOLLERAT DU JEU, XAVIER;SIGNING DATES FROM 20180801 TO 20181001;REEL/FRAME:047036/0055

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: ADVISORY ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION